美聯儲副主席傑斐遜：美國並未免受與石油相關的能源衝擊。

A股存儲芯片板塊部分回暖，華虹公司漲超10%，中芯國際漲超4%，商絡電子、利和興、深科達漲幅居前。

At a May 28 regular press briefing, the Ministry of Natural Resources published and explained the Guiding Opinions on Accelerating High-Quality Development of Marine Drugs and Functional Products. On intellectual property protection, Yu Jiangyong, deputy director of the Drugs Registration Management Department at the National Medical Products Administration (NMPA), said the NMPA and the China National Intellectual Property Administration (CNIPA) have established an early-resolution mechanism for drug patent disputes. The newly revised Implementing Regulations of the PRC Drug Administration Law (the Regulations) further strengthen protection for drug trial data and establish a market exclusivity-period system for pediatric medicines and drugs for rare diseases. The Measures for the Protection of Drug Trial Data took effect simultaneously with the Regulations on May 15, and the Regulations’ specific implementation documents for the market exclusivity system are currently being intensively drafted. NMPA said these measures will further bolster IP protection for innovative drugs and stimulate firms’ innovation momentum in marine drug R&D.